What is FLUIDDA?
Fluidda is a recognized leader in the field of Functional Respiratory Imaging (FRI), dedicated to deepening the understanding of lung pathology and physiology to enhance respiratory treatment strategies. The company offers cutting-edge solutions for healthcare professionals, including personalized medicine approaches and advanced diagnostic tools designed to improve patient outcomes and reduce overall healthcare expenditures. By collaborating with pharmaceutical and biotech firms, Fluidda aims to accelerate drug development pipelines and positively impact the lives of individuals suffering from respiratory ailments globally. Their proprietary technology integrates sophisticated imaging techniques with artificial intelligence to generate critical insights that support the development of more effective treatment pathways.
How much funding has FLUIDDA raised?
FLUIDDA has raised a total of $2M across 1 funding round:
Other Financing Round
$2M
Other Financing Round (2019): $2M with participation from Materialise
Key Investors in FLUIDDA
Materialise
Materialise, founded in 1990 and headquartered in Flanders, Belgium, is a significant player in the 3D printing industry, providing advanced manufacturing solutions that likely align with Fluidda's innovative imaging technology.
What's next for FLUIDDA?
The substantial enterprise-level funding indicates FLUIDDA is poised for significant scaling and further innovation in the competitive respiratory health market. This capital injection is expected to fuel advancements in their FRI platform, potentially expanding its application in clinical trials and personalized treatment plans. Strategic partnerships and continued investment in AI-driven diagnostics will likely be key to their future growth, solidifying their position as a critical player in optimizing respiratory care and drug development.
See full FLUIDDA company page
